Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

PF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 within the Roche research and development programs) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the risk that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have dec
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... 2014 Back in the 1970’s, many companies ... per employee, which included space for circulation and file storage. ... Howell, partner at Nidea Corporate Real Estate / ITRA ... the year 2000, however, 250 square feet per employee ... come down to 175 to 225 square feet, and over ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Ill., June 30 Hospira, Inc. (NYSE: ... company, today announced agreements with MedAssets on intravenous (I.V.) ... its agreement for infusion devices. The five-year MedAssets agreements ... solutions and equipment, and July 1, 2009, for infusion ...
... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
... Limited, the decentralised and point-of-care molecular diagnostics company, announced today ... Veterinary Laboratories Agency to evaluate the performance of the Enigma ... be one of the main threats to cattle (1), affecting ... closely related to classical swine fever virus, a serious disease ...
Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency 2Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency 3
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
(Date:9/30/2014)... involving mice and published in the October 2014 issue ... , suggests that just because you can do it, ... of Italian scientists have found that using marijuana in ... system. This damage may result in autoimmune diseases and ... disease and rheumatoid arthritis in adulthood. , "I hope ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... blood cell production and function will today be awarded ... Council,s (NHMRC) program grants scheme. The nine ... securing $107 million in program grant funding will be ... the Federal Minister for Mental Health and Ageing, the ...
... Parachin and the secret of her technique is enzymes that ... made from xylose then ethanol production could increase by over ... friendly fuel. Ethanol is manufactured by fermenting sugars from ... the second most common type of sugar found in nature. ...
... -- Software agents on assignment . . . ... organization,s network could be more secure with a system ... Oak Ridge National Laboratory,s Computational Sciences and Engineering Division. ... are being copied, excerpted, changed and stored in various ...
Cached Biology News:$38.4M NHMRC program grants extend cancer and blood cell research 2Enzymes from garden compost could favour bioethanol production 2Story tips from the US Department of Energy's Oak Ridge National Laboratory March 2011 2
... Motic's B3 series of microscopes offer ... microscope required for laboratory work. Equipped with ... Super Contrast (ASC) objectives. The B3 is ... The Siedentopf binocular tube eliminates the need ...
... SYBR Green II RNA gel ... gel stain that has bright fluorescence when ... gels, making it ideal for use with ... scanners or standard UV transilluminators. A 500 ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... Glutathion-S-transferases (GST) are a group ... the detoxification processes. The GSTs are ... Pi, Teta and microsomal. The classes ... and s Sample Size: ...
Biology Products: